Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Amgen Inc. is a leading biotechnology company focused on developing innovative therapies for serious illnesses, particularly in oncology and nephrology. Its competitive position is strengthened by a robust pipeline of biologics, including its flagship product, Enbrel, and emerging therapies like Tezepelumab for asthma, which leverage advanced genetic engineering and a strong patent portfolio.
Amgen generates revenue primarily through the sale of biologic drugs, which command premium pricing due to their complexity and the high barriers to entry in the biotech sector. The company's strong R&D capabilities allow it to maintain a competitive edge, while its established relationships with healthcare providers ensure robust distribution channels.
FDA approval of new drugs or indications, particularly in oncology and rare diseases
Market share shifts in key therapeutic areas, such as rheumatoid arthritis or cancer
Changes in pricing regulations or reimbursement policies affecting biologics
M&A activity in the biotech space that could enhance Amgen's pipeline or market position
Regulatory changes that could impact drug pricing and reimbursement
Technological disruption from new treatment modalities, such as gene therapy or personalized medicine
Increased competition from biosimilars and emerging biotech firms
Potential for loss of exclusivity on key products leading to revenue declines
High debt levels relative to equity could pose risks if cash flows decline
Pension obligations that may impact liquidity in adverse market conditions
moderate - Amgen's products are essential for chronic and serious conditions, which provides some insulation from economic downturns, but overall healthcare spending trends can be influenced by GDP growth.
Higher interest rates could increase Amgen's cost of capital, impacting R&D investments and potentially leading to lower growth rates in new product development.
minimal - Amgen has a strong balance sheet with significant cash reserves, reducing reliance on external credit.
growth - due to Amgen's strong pipeline and potential for significant revenue growth from new therapies.
moderate - historical volatility has been lower than the broader biotech sector, but can spike around clinical trial results or regulatory decisions.
